NanoViricides (NYSE:NNVC) Trading 4.3% Higher – Time to Buy?

Posted by MarketBeat News on Oct 5th, 2024

Shares of NanoViricides, Inc. (NYSE:NNVC – Get Free Report) shot up 4.3% on Friday . The company traded as high as $1.47 and last traded at $1.47. 84,449 shares traded hands during trading, a decline of 54% from the average session volume of 183,288 shares. The stock had previously closed at $1.41.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered NanoViricides from a “hold” rating to a “sell” rating in a report on Wednesday, July 17th.

Get Our Latest Research Report on NNVC

NanoViricides Price Performance

Want More Great Investing Ideas?

The company has a market cap of $17.37 million, a PE ratio of -1.79 and a beta of 0.94. The company has a fifty day moving average price of $1.78 and a 200 day moving average price of $1.77.

NanoViricides (NYSE:NNVC – Get Free Report) last issued its quarterly earnings data on Friday, September 27th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NanoViricides stock. Moss Adams Wealth Advisors LLC acquired a new position in shares of NanoViricides, Inc. (NYSE:NNVC – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,000 shares of the company’s stock, valued at approximately $26,000. Moss Adams Wealth Advisors LLC owned approximately 0.13% of NanoViricides at the end of the most recent quarter. Institutional investors and hedge funds own 10.30% of the company’s stock.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.